Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. - Test2 - elhamkhani - TriplyDB

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

http://www.wikidata.org/entity/Q46694340

about

Is there more to BARD1 than BRCA1?Linking the ovarian cancer transcriptome and immunome Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes.Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue.Gene expression profiling of rat spermatogonia and Sertoli cells reveals signaling pathways from stem cells to niche and testicular cancer cells to surrounding stroma.HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers Association of three common BARD1 variants with cancer susceptibility: a system review and meta-analysis.BARD1 mediates TGF-β signaling in pulmonary fibrosis.Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability.Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.Alternative splicing in cancer: implications for biology and therapy.Regulation of transcription by synthetic DNA-bending agents.Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX.BARD1: an independent predictor of survival in non-small cell lung cancer.A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens.BARD1 serum autoantibodies for the detection of lung cancer.Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling.Dualistic Role of BARD1 in Cancer.BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.Preoperative high-intensity training in frail old patients undergoing pulmonary resection for NSCLC.Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.Clinical diagnosis of malignant pleural mesothelioma.

P2860

Q28236135-7AD1F1D4-951F-4C8A-BFF8-2A70608553B8 Q33313203-587FD85F-B81A-47D6-A57B-EEA89AEED55F Q33329750-F10D8678-7087-4C9E-9AE8-3CEE5DDF55A6 Q33723629-44DC6810-C04F-47B3-AF79-ACA8D391432A Q33792623-4C82A246-8913-4A35-A5EA-7BA3B56668D4 Q35070712-A02C6E6C-6D00-41AB-AD12-3DA07B1564AA Q35151124-BCC156D1-F053-4D8B-85C6-DBC76028299B Q35173448-B66F7794-EBB5-4D51-A0A5-75EA52421841 Q36105254-278A2025-801A-43DF-869F-A13D1CD2C43E Q36166792-32F7EE3C-F238-4CAC-A213-694F12183248 Q37705964-FC8CF347-F5EA-4537-B159-824E39CD9AC4 Q37940719-B1ECC600-6F4C-4FB4-A4DC-5B110C53D0EE Q38179828-07C7FCD1-9653-42C9-A17F-F062B95FAFEE Q38309182-11CDCD9C-E1AA-4D3E-92EE-97DF15F01FF3 Q39118191-87356DC5-DDEE-4F2A-99AC-AF688344AE4F Q39495392-DC09EE6C-CDFF-4662-92F3-C94E22A60C98 Q39980425-75E5B7F5-B109-49CB-888A-C3A4F4B6CC04 Q41281453-B17113B3-10BF-42B5-A94A-71BE4AECDF27 Q41332112-2A209EBC-6698-4CFC-A1BE-45DFEDCB2A4E Q47177315-B3DAA992-673F-4F35-93E0-73646FFE82FF Q49612029-990A9A4D-8521-431C-91EB-9A00C51AD218 Q51832091-B80B8EB2-7EDE-4B53-91B9-14CE74008E4C Q51837133-C86E8D6B-7836-41D9-B236-65322F48CD66 Q52672895-F7AB0280-B6AD-43C2-A1E4-4D78D2E4E081

P2860

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

http://www.wikidata.org/entity/Q46694340

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

@en

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

@nl

type

label

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

@en

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

@nl

prefLabel

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

@en

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

@nl

P1433

Q46694340-D8C1C733-8887-401F-850C-9DD30DAEA3FE

P1476

Q46694340-C4F60CB1-56A1-40F5-921F-8B3BAB4F8487

P2093

Q46694340-77568E74-CFD1-458E-AD76-74037BDBB7C0

Q46694340-82617F3B-8969-4B86-B33D-5A007DDCF256

Q46694340-B8CEA530-FFC6-4150-A7F1-22574B43708B

Q46694340-CCEF5F04-29F6-478D-A521-727333825606

Q46694340-E903BC95-D655-48C0-A4B3-DF16CA3432F0

Q46694340-F4623B67-CD7A-4F28-A7FB-989AC001B0A4

Q46694340-F95B25DB-B359-48CC-8A7E-208440F09506

P2860

Q46694340-05444871-FD48-471C-A5E3-466D4E1FDEB9

Q46694340-076D37DA-AAC7-4657-8D4A-2A755B49E129

Q46694340-0DCBBE93-2DBD-4190-98B7-276D156F5124

Q46694340-11635B0B-6F43-4919-87F1-0D63DDFA30E6

Q46694340-1DE84150-99AB-46A7-B345-814B515CB8E7

Q46694340-21E32710-D7D8-4DD0-8C2E-8DD36192770C

Q46694340-2A1A6F07-1459-4DEC-8BD0-9EF549C24636

Q46694340-2C773F11-D52C-46F2-8995-7E926356867E

Q46694340-339FBF35-B19C-4EF8-8602-4CBE275F80FF

Q46694340-353BF3A1-ED77-48D5-85EA-4BC4E9C2CE0A

P304

Q46694340-CC94779D-D3B1-42A6-A9E1-E91DC0C7809B

P31

Q46694340-3EC6AF3D-99DC-4731-A54E-00EDDC9135EA

P356

Q46694340-C964B3AE-F23E-4023-9DC6-34995733860B

P433

Q46694340-2FC0F1F2-E902-4AF4-97AD-485426048C54

P478

Q46694340-2C20FCA1-2D5E-4F1C-9C16-C9B8AB70B8CD

P50

Q46694340-2475AFC6-2938-4CE0-8BEF-D8A2E7A7BFC0

P577

Q46694340-76E9FFEF-1A77-4AE6-9DCA-C42827958AF1

P5875

Q46694340-CD3030F4-6C5C-44F9-89C9-8CF70DD6DAA7

P698

Q46694340-7F362D75-2F17-4AB9-AD0E-8656B139C414

P921

Q46694340-456A3766-E069-4696-B2BA-3E9621D303CE

P356

P1433

International Journal of Cancer

P1476

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis

@en

P2093

Andrea Bianco

http://www.w3.org/2001/XMLSchema#string

Anne-Therese Vlastos

http://www.w3.org/2001/XMLSchema#string

Geoffrey J Laurent

http://www.w3.org/2001/XMLSchema#string

Irmgard Irminger-Finger

http://www.w3.org/2001/XMLSchema#string

Jian-Yu Wu

http://www.w3.org/2001/XMLSchema#string

Karl-Heinz Krause

http://www.w3.org/2001/XMLSchema#string

Marie-Françoise Pelte

http://www.w3.org/2001/XMLSchema#string

P2860

Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50

BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention

Identification of a RING protein that can interact in vivo with the BRCA1 gene product

Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation

Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase

Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis

The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity

P304

1215-1226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.21428

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Maria Adelaide Caligo

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7609309

http://www.w3.org/2001/XMLSchema#string

P698

16152612

http://www.w3.org/2001/XMLSchema#string

P921